Physiology and pathophysiology of liver lipid metabolism

References

• Perry RJ, Samuel VT, Petersen KF, et al. The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes. Nature 2014;510:84-91
   PubMed Web of Science ®Google Scholar
• Heart. Available from: www.heart.org/HEARTORG/Conditions/Cholesterol/PreventionTreatmentofHighCholesterol/Know-Your-FatsUCM305628Article.jsp
   Google Scholar
• Timlin MT, Parks EJ. Temporal pattern of de novo lipogenesis in the postprandial state in healthy men. Am J Clin Nutr 2005;81:35-42
   PubMed Web of Science ®Google Scholar
• Hui DY. Molecular mechanisms of cholesterol absorption and transport in the intestine. Semin Cell Dev Biol 2005;16:183-92
   PubMed Web of Science ®Google Scholar
• Merkel M, Eckel RH, Goldberg IJ. Lipoprotein lipase: genetics, lipid uptake, and regulation. J Lipid Res 2002;43:1997-2006
   PubMed Web of Science ®Google Scholar
• Goldberg IJ. Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis. J Lipid Res 1996;37:693-707
   PubMed Web of Science ®Google Scholar
• Zhang SH, Reddick RL, Piedrahita JA, et al. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 1992;258:468-71
   PubMed Web of Science ®Google Scholar
• Redgrave TG, Vassiliou GG, Callow MJ. Cholesterol is necessary for triacylglycerol–phospholipid emulsions to mimic the metabolism of lipoproteins. Biochim Biophys Acta 1987;921:154-9
   PubMed Web of Science ®Google Scholar
• Hebbachi AM, Gibbons GF. Microsomal membrane-associated apoB is the direct precursor of secreted VLDL in primary cultures of rat hepatocytes. J Lipid Res 2001;42:1609-17
   PubMed Web of Science ®Google Scholar
• Herz J, Qiu SQ, Oesterle A, et al. Initial hepatic removal of chylomicron remnants is unaffected but endocytosis is delayed in mice lacking the low density lipoprotein receptor. Proc Natl Acad Sci USA 1995;92:4611-15
   PubMed Web of Science ®Google Scholar
• Kobayashi K, Oka K, Forte T, et al. Reversal of hypercholesterolemia in low density lipoprotein receptor knockout mice by adenovirus-mediated gene transfer of the very low density lipoprotein receptor. J Biol Chem 1996;271:6852-60
   PubMed Web of Science ®Google Scholar
• Ginsberg HN. Lipoprotein metabolism and its relationship to atherosclerosis. Med Clin North Am 1994;78:1-20
   PubMed Web of Science ®Google Scholar
• Wang N, Silver DL, Costet P. Specific binding of ApoA1, enhanced cholesterol efflux and altered plasma membrane morphology in cells expressing ABCA1. J Biol Chem 2000;275:33053-8
   PubMed Web of Science ®Google Scholar
• Rigotti A, Trigatti B, Babitt J, et al. Scavenger receptor BI – a cell surface receptor for high density lipoprotein. Curr Opin Lipidol 1997;8:181-8
   PubMed Web of Science ®Google Scholar
• Fielding CJ, Shore VG, Fielding PE. A protein cofactor of lecithin: cholesterol acyltransferase. Biochem Biophys Res 1972;46:1493-8
   PubMed Web of Science ®Google Scholar
• Pattnaik NM, Montes A, Hughes LB, et al. Cholesteryl ester exchange protein in human plasma isolation and characterization. Biochim Biophys Acta 1978;530:428-38
   PubMed Web of Science ®Google Scholar
• Jauhiainen M, Metso J, Pahlman R, et al. Human plasma phospholipid transfer protein causes high density lipoprotein conversion. J Biol Chem 1993;268:40324036
   Web of Science ®Google Scholar
• Daniels TF, Killinger KM, Michal JJ, et al. Lipoproteins, cholesterol homeostasis and cardiac health. Int J Biol Sci 2009;5:474-48
   PubMed Web of Science ®Google Scholar
• Dijkstra Albert J, Hamilton RJ, Hamm W. ‘Fatty Acid Biosynthesis.’ Trans Fatty Acids. Blackwell Pub; Oxford: 2008
   Google Scholar
• Lodhi IJ, Wei X, Semenkovich CF. Lipoexpediency: de novo lipogenesis as a metabolic signal transmitter. Trends Endocrinol Metab 2011;22:1-8
   PubMed Web of Science ®Google Scholar
• Knight BL, Hebbachi A, Hauton D, et al. A role for PPARalpha in the control of SREBP activity and lipid synthesis in the liver. Biochem J 2005;389:413-21
   PubMed Web of Science ®Google Scholar
• Schadinger SE, Bucher NL, Schreiber BM, et al. PPARgamma2 regulates lipogenesis and lipid accumulation in steatotic hepatocytes. Am J Physiol Endocrinol Metab 2005;288:1195-205
   PubMed Web of Science ®Google Scholar
• Shen LL, Liu H, Peng J, et al. Effects of farnesoid X receptor on the expression of the fatty acid synthetase and hepatic lipase. Mol Biol Rep 2011;38:553-9
   PubMed Web of Science ®Google Scholar
• Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990;343:425-30
   PubMed Web of Science ®Google Scholar
• Xu X, Jae-Seon S, Jong-Gil P, et al. Transcriptional control of hepatic lipid metabolism by SREBP and ChREBP. Semin Liver Dis 2013;33:301-11
   PubMed Web of Science ®Google Scholar
• Schwarz JM, Linfoot P, Dare D, et al. Hepatic de novo lipogenesis in normoinsulinemic and hyperinsulinemic subjects consuming high-fat, low-carbohydrate and low-fat, high-carbohydrate isoenergetic diets. Am J Clin Nutr 2003;77:43-50
   PubMed Web of Science ®Google Scholar
• Strable MS, Ntambi JM. Genetic control of de novo lipogenesis: role in diet-induced obesity. Crit Rev Biochem Mol Biol 2010;45:199-214
   PubMed Web of Science ®Google Scholar
• Kersten S. Mechanisms of nutritional and hormonal regulation of lipogenesis. EMBO Rep 2001;2:282-6
   PubMed Web of Science ®Google Scholar
• Herman MA, Peroni OD, Villoria J, et al. A novel ChREBP isoform in adipose tissue regulates systemic glucose metabolism. Nature 2012;484:333-8
   PubMed Web of Science ®Google Scholar
• Jump DB, Clarke SD, Thelen A, et al. Coordinate regulation of glycolytic and lipogenic gene expression by polyunsaturated fatty acids. J Lipid Res 1994;35:1076-84
   PubMed Web of Science ®Google Scholar
• Neese RA, Faix D, Kletke C, et al. Measurement of endogenous synthesis of plasma cholesterol in rats and humans using MIDA. Am J Physiol 1993;264:136-47
   PubMedGoogle Scholar
• Xie C, Turley SD, Dietschy JM. Centripetal cholesterol flow from the extrahepatic organs through the liver is normal in mice with mutated Niemann-Pick type C protein (NPC1). J Lipid Res 2000;41:278-1289
   Web of Science ®Google Scholar
• Jones PJ, Schoeller DA. Evidence for diurnal periodicity in human cholesterol synthesis. J Lipid Res 1990;31:667-73
   PubMed Web of Science ®Google Scholar
• Neuschwander-Tetri BA. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology 2010;52:774-88
   PubMed Web of Science ®Google Scholar
• Wilfling F, Haas JT, Walther TC, et al. Lipid droplet biogenesis. Curr Opin Cell Biol 2014;29:39-45
   PubMed Web of Science ®Google Scholar
• Aon MA, Bhatt N, Cortassa SC. Mitochondrial and cellular mechanisms for managing lipid excess. Front Physiol 2014;5:282
   PubMed Web of Science ®Google Scholar
• Berk PD. Regulatable fatty acid transport mechanisms are central to the pathophysiology of obesity, fatty liver, and metabolic syndrome. Hepatology 2008;48:1362-76
   PubMed Web of Science ®Google Scholar
• Finn PF, Dice JF. Proteolytic and lipolytic responses to starvation. Nutrition 2006;22:830-44
   PubMed Web of Science ®Google Scholar
• Postic C, Girard J. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance. Lessons from genetically engineered mice. J Clin Invest 2008;118:829-38
   PubMed Web of Science ®Google Scholar
• Nguyen P, Leray V, Diez M, et al. Liver lipid metabolism. J Anim Physiol Anim Nutr 2008;92:272-83
   PubMed Web of Science ®Google Scholar
• Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120:1640-5
   PubMed Web of Science ®Google Scholar
• Simmons RK, Alberti KG, Gale EA, et al. The metabolic syndrome: useful concept or clinical tool? Report of a WHO Expert Consultation. Diabetologia 2010;53:600-5
   PubMed Web of Science ®Google Scholar
• Kotronen A, Westerbacka J, Bergholm R, et al. Liver fat in the metabolic syndrome. J Clin Endocrinol Metab 2007;92:3490-7
   PubMed Web of Science ®Google Scholar
• Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012;55:2005-23
   PubMed Web of Science ®Google Scholar
• Larter CZ, Chitturi S, Heydet D, et al. A fresh look at NASH pathogenesis. Part1: the metabolic movers. J Gastroenterol Hepatol 2010;25:672-90
   PubMed Web of Science ®Google Scholar
• Yki-Järvinen H. Pathophysiology of type 2 diabetes. In: Wass JAH, Stewart PM, Amiel SA, Davies MC, oxford textbook of endocrinology and diabetes. Oxford University Press; Oxford: 2011
   Google Scholar
• Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol 2013;10:330-44
   PubMed Web of Science ®Google Scholar
• Choi JH, Rhee EJ, Bae JC, et al. Increased risk of type 2 diabetes in subjects with both elevated liver enzymes and ultrasonographically diagnosed nonalcoholic fatty liver disease: a 4-year longitudinal study. Arch Med Res 2013;44:115-20
   PubMed Web of Science ®Google Scholar
• Park SK, Seo MH, Shin HC, Ryoo JH. Clinical availability of nonalcoholic fatty liver disease as an early predictor of type 2 diabetes mellitus in Korean men: 5-year prospective cohort study. Hepatology 2013;57:1378-83
   PubMed Web of Science ®Google Scholar
• Brunt EM, Kleiner DE, Wilson LA, et al. NASH Clinical Research Network (CRN). Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology 2011;53:810-20
   PubMed Web of Science ®Google Scholar
• Patton HM, Yates K, Unalp-Arida A, et al. Association between metabolic syndrome and liver histology among children with nonalcoholic fatty liver disease. Am J Gastroenterol 2010;105:2093-102
   PubMed Web of Science ®Google Scholar
• Argo CK, Northup PG, Al-Osaimi AM, et al. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J Hepatol 2009;51:371-9
   PubMed Web of Science ®Google Scholar
• Pais R, Charlotte F, Fedchuk L, et al. A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. J Hepatol 2013;59:550-6
   PubMed Web of Science ®Google Scholar
• Petersen KF, Dufour S, Savage DB, et al. The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome. Proc Natl Acad Sci USA 2007;104:12587-94
   PubMed Web of Science ®Google Scholar
• Cohen DE, Fisher EA. Lipoprotein metabolism, dyslipidemia, and nonalcoholic fatty liver disease. Semin Liver Dis 2013;33:380-8
   PubMed Web of Science ®Google Scholar
• Lewis GF, Murdoch S, Uffelman K, et al. Hepatic lipase mRNA, protein, and plasma enzyme activity is increased in the insulin-resistant, fructose-fed Syrian golden hamster and is partially normalized by the insulin sensitizer rosiglitazone. Diabetes 2004;53:2893-900
   PubMed Web of Science ®Google Scholar
• Miksztowicz V, Lucero D, Zago V, et al. Hepatic lipase activity is increased in non-alcoholic fatty liver disease beyond insulin resistance. Diabetes Metab Res Rev 2012;28:535-41
   PubMed Web of Science ®Google Scholar
• Lucero D, Zago V, López GI, et al. Does non-alcoholic fatty liver impair alterations of plasma lipoproteins and associated factors in metabolic syndrome? Clin Chim Acta 2011;412:587-92
   PubMed Web of Science ®Google Scholar
• Tzotzas T, Desrumaux C, Lagrost L. Plasma phospholipid transfer protein (PLTP): review of an emerging cardiometabolic risk factor. Obes Rev 2009;10:403-11
   PubMed Web of Science ®Google Scholar
• Xiao C, Watanabe T, Zhang Y, et al. Enhanced cellular uptake of remnant high-density lipoprotein particles: a mechanism for high-density lipoprotein lowering in insulin resistance and hypertriglyceridemia. Circ Res 2008;103:159-66
   PubMed Web of Science ®Google Scholar
• Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006;444:860-7
   PubMed Web of Science ®Google Scholar
• Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest 2005;115:1111-19
   PubMed Web of Science ®Google Scholar
• Xu H, Barnes GT, Yang Q, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003;112:1821-30
   PubMed Web of Science ®Google Scholar
• Day CP, James OF. Steatohepatitis: a tale of two ‘hits’? Gastroenterology 1998;114:842-5
   PubMed Web of Science ®Google Scholar
• Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 2010;52:1836-46
   PubMed Web of Science ®Google Scholar
• Yamaguchi K, Yang L, McCall S, et al. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with non-alcoholic steatohepatitis. Hepatology 2007;45:1366-74
   PubMed Web of Science ®Google Scholar
• Peretti N, Sassolas A, Roy CC, et al. Guidelines for the diagnosis and management of chylomicron retention disease based on a review of the literature and the experience of two centers. Adv Clin Chem 2011;54:81-107
   PubMedGoogle Scholar
• Ricchi M, Odoardi MR, Carulli L, et al. Differential effect of oleic and palmitic acid on lipid accumulation and apoptosis in cultured hepatocytes. J Gastroenterol Hepatol 2009;24:830-40
   PubMed Web of Science ®Google Scholar
• Han MS, Park SY, Shinzawa K, et al. Lysophosphatidylcholine as a death effector in the lipoapoptosis of hepatocytes. J Lipid Res 2008;49:84-97
   PubMed Web of Science ®Google Scholar
• Donnelly KL, Smith CI, Schwarzenberg SJ, et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005;115:1343-51
   PubMed Web of Science ®Google Scholar
• Bechmann LP, Gieseler RK, Sowa JP, et al. Apoptosis is associated with CD36/fatty acid translocase upregulation in non-alcoholic steatohepatitis. Liver Int 2010;30:850-9
   PubMed Web of Science ®Google Scholar
• Bieghs V, Wouters K, van Gorp PJ, et al. Role of scavenger receptor A and CD36 in diet-induced nonalcoholic steatohepatitis in hyperlipidemic mice. Gastroenterology 2010;138:2477-86
   PubMed Web of Science ®Google Scholar
• Berk PD, Zhou S, Bradbury MW. Increased hepatocellular uptake of long chain fatty acids occurs by different mechanisms in fatty livers due to obesity or excess ethanol use, contributing to development of steatohepatitis in both settings. Trans Am Clin Climatol Assoc 2005;116:335-44
   PubMedGoogle Scholar
• Sookoian S, Pirola CJ. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology 2011;53:1883-94
   PubMed Web of Science ®Google Scholar
• Dubuquoy C, Burnol AF, Moldes M. PNPLA3, a genetic marker of progressive liver disease, still hiding its metabolic function? Clin Res Hepatol Gastroenterol 2013;37:30-5
   PubMed Web of Science ®Google Scholar
• Kumari M, Schoiswohl G, Chitraju C, et al. Adiponutrin functions as a nutritionally regulated lysophosphatidic acid acyltransferase. Cell Metab 2012;15:691-702
   PubMed Web of Science ®Google Scholar
• Li JZ, Huang Y, Karaman R, et al. Chronic overexpression of PNPLA3I148M in mouse liver causes hepatic steatosis. J Clin Invest 2012;122:4130-44
   PubMed Web of Science ®Google Scholar
• Robertson G, Leclercq I, Farrell GC. Nonalcoholic steatosis and steatohepatitis. II. Cytochrome P-450 enzymes and oxidative stress. Am J Physiol Gastrointest Liver Physiol 2001;281:1135-9
   PubMed Web of Science ®Google Scholar
• Kohjima M, Enjoji M, Higuchi N, et al. Reevaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease. Int J Mol Med 2007;20:351-8
   PubMed Web of Science ®Google Scholar
• Sunny NE, Parks EJ, Browning JD, et al. Excessive hepatic mitochondrial TCA cycle and gluconeogenesis in humans with nonalcoholic fatty liver disease. Cell Metab 2011;14:804-10
   PubMed Web of Science ®Google Scholar
• Pérez-Carreras M, Del Hoyo P, Martín MA, et al. Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis. Hepatology 2003;38:999-1007
   PubMed Web of Science ®Google Scholar
• Wei Y, Rector RS, Thyfault JP, et al. Nonalcoholic fatty liver disease and mitochondrial dysfunction. World J Gastroenterol 2008;14:193-9
   PubMed Web of Science ®Google Scholar
• Caldwell SH, De Freitas LA, Park SH, et al. Intramitochondrial crystalline inclusions in nonalcoholic steatohepatitis. Hepatology 2009;49:1888-95
   PubMed Web of Science ®Google Scholar
• Schmid AI, Szendroedi J, Chmelik M, et al. Liver ATP synthesis is lower and relates to insulin sensitivity in patients with type 2 diabetes. Diabetes Care 2011;34:448-53
   PubMed Web of Science ®Google Scholar
• Noguchi Y, Young J, Aleman J, et al. Effect of anaplerotic fluxes and amino acid availability on hepatic lipoapoptosis. J Biol Chem 2009;284:33425-36
   PubMed Web of Science ®Google Scholar
• Hardy S, El-Assaad W, Przybytkowski E, et al. Saturated fatty acid-induced apoptosis in MDA-MB-231 breast cancer cells – A role for cardiolipin. J Biol Chem 2003;278:31861-70
   PubMed Web of Science ®Google Scholar
• Choi S-E, Jung I-R, Lee Y-J, et al. Stimulation of lipogenesis as well as fatty acid oxidation protects against palmitate-induced INS-1 beta-cell death. Endocrinology 2011;152:816-27
   PubMed Web of Science ®Google Scholar
• Weltman MD, Farrell GC, Hall P, et al. Hepatic cytochrome p450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology 1998;27:128-33
   PubMed Web of Science ®Google Scholar
• Lambertucci RH, Hirabara SM, Silveira L dos R, et al. Palmitate increases superoxide production through mitochondrial electron transport chain and NADPH oxidase activity in skeletal muscle cells. Cell Physiol 2008;216:796-804
   Google Scholar
• Gregor MF, Yang L, Fabbrini E, et al. Endoplasmic reticulum stress is reduced in tissues of obese subjects after weight loss. Diabetes 2009;58:693-700
   PubMed Web of Science ®Google Scholar
• Puri P, Mirshahi F, Cheung O, et al. Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease. Gastroenterology 2008;134:568-76
   PubMed Web of Science ®Google Scholar
• Sharma NK, Das SK, Mondal AK, et al. Endoplasmic reticulum stress markers are associated with obesity in nondiabetic subjects. J Clin Endocrinol Metab 2008;93:4532-41
   PubMed Web of Science ®Google Scholar
• Spector AA, Yorek MA. Membrane lipid-composition and cellular function. J Lipid Res 1985;26:1015-35
   PubMed Web of Science ®Google Scholar
• Zhang K, Kaufman RJ. The unfolded protein response: a stress signaling pathway critical for health and disease. Neurology 2006;66:102-9
   PubMed Web of Science ®Google Scholar
• Ozcan U, Cao Q, Yilmaz E, et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 2004;306:457-61
   PubMed Web of Science ®Google Scholar
• Kaufman RJ. Orchestrating the unfolded protein response in health and disease. J Clin Invest 2002;110:1389-98
   PubMed Web of Science ®Google Scholar
• Scorrano L, Oakes SA, Opferman JT, et al. BAX and BAK regulation of endoplasmic reticulum Ca2+: a control point for apoptosis. Science 2003;300:135-9
   PubMed Web of Science ®Google Scholar
• Ron D, Walter P. Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol 2007;8:519-29
   PubMed Web of Science ®Google Scholar
• Endo M, Masaki T, Seike M, et al. TNF-alpha induces hepatic steatosis in mice by enhancing gene expression of sterol regulatory element binding protein-1c (SREBP-1c). Exp Biol Med 2007;232:614-21
   PubMed Web of Science ®Google Scholar
• Crespo J, Cayon A, Fernandez-Gil P, et al. Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology 2001;34:1158-16
   PubMed Web of Science ®Google Scholar
• Novak TE, Babcock TA, Jho DH, et al. NF-kappa B inhibition by omega -3 fatty acids modulates LPS-stimulated macrophage TNF-alpha transcription. Am J Physiol Lung Cell Mol Physiol 2003;284:L84-9
   PubMed Web of Science ®Google Scholar
• Senn JJ. Toll-like receptor-2 is essential for the development of palmitate-induced insulin resistance in myotubes. J Biol Chem 2006;281:26865-75
   PubMed Web of Science ®Google Scholar
• Deng J, Lu PD, Zhang Y, et al. Translational repression mediates activation of nuclear factor kappa B by phosphorylated translation initiation factor 2. Mol Cell Biol 2004;24:10161-8
   PubMed Web of Science ®Google Scholar
• Yamazaki H, Hiramatsu N, Hayakawa K, et al. Activation of the Akt-NF-kappaB pathway by subtilase cytotoxin through the ATF6 branch of the unfolded protein response. J Immunol 2009;183:1480-7
   PubMed Web of Science ®Google Scholar
• Lesmana CRA, Hasan I, Budihusodo U, et al. Diagnostic value of a group of biochemical markers of liver fibrosis in patients with non-alcoholic steatohepatitis. J Dig Dis 2009;10:201-6
   PubMed Web of Science ®Google Scholar
• Hui JM, Hodge A, Farrell GC, et al. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology 2004;40:46-54
   PubMed Web of Science ®Google Scholar
• Wieckowska A, Papouchado BG, Li Z, et al. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am J Gastroenterol 2008;103:1372-9
   PubMed Web of Science ®Google Scholar
• Haukeland JW, Damås JK, Konopski Z, et al. Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. J Hepatol 2006;44:1167-74
   PubMed Web of Science ®Google Scholar
• Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993;259:87-91
   PubMed Web of Science ®Google Scholar
• Kern PA, Saghizadeh M, Ong JM, et al. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 1995;95:2111-19
   PubMed Web of Science ®Google Scholar
• Tailleux A, Wouters K, Staels B. Roles of PPARs in NAFLD: potential therapeutic targets. Triglyceride Metab Dis 2012;1821:809-18
   Google Scholar
• Vanden Berghe W, Vermeulen L, Delerive P, et al. A paradigm for gene regulation: inflammation, NF-kappaB and PPAR. Adv Exp Med Biol 2003;544:181-96
   PubMed Web of Science ®Google Scholar
• Malhi H, Gores GJ. Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. Semin Liver Dis 2008;28:360-9
   PubMed Web of Science ®Google Scholar
• Zhou SL, Stump D, Sorrentino D, et al. Adipocyte differentiation of 3T3-L1 cells involves augmented expression of a 43-kDa plasma membrane fatty acid-binding protein. J Biol Chem 1992;267:14456-1446
   PubMed Web of Science ®Google Scholar
• Kaser S, Moschen A, Cayon A, et al. Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut 2005;54:117-21
   PubMed Web of Science ®Google Scholar
• Berlanga A, Guiu-Jurado E, Porras JA, et al. Molecular pathways in non-alcoholic fatty liver disease. Clin Exp Gastroenterol 2014;7:221-39
   PubMedGoogle Scholar
• Westerbacka J, Kolak M, Kiviluoto T, et al. Genes involved in fatty acid partitioning and binding, lipolysis, monocyte/macrophage recruitment, and inflammation are overexpressed in the human fatty liver of insulin-resistant subjects. Diabetes 2007;56:2759-65
   PubMed Web of Science ®Google Scholar
• Mallat A, Teixeira-Clerc F, Deveaux V, et al. The endocannabinoid system as a key mediator during liver diseases: new insights and therapeutic openings. Br J Pharmacol 2011;163:1432-40
   PubMed Web of Science ®Google Scholar
• Osei-Hyiaman D, Liu J, Zhou L, et al. Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice. J Clin Invest 2008;118:3160-9
   PubMed Web of Science ®Google Scholar
• Tam J, Vemuri VK, Liu J, et al. Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. J Clin Invest 2010;120:2953-66
   PubMed Web of Science ®Google Scholar
• Gary-Bobo M, Elachouri G, Gallas JF, et al. Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats. Hepatology 2007;46:122-9
   PubMed Web of Science ®Google Scholar
• Jourdan T, Demizieux L, Gresti J, et al. Antagonism of peripheral hepatic cannabinoid receptor-1 improves liver lipid metabolism in mice: evidence from cultured explants. Hepatology 2012;55:790-9
   Google Scholar
• Auguet T, Terra X, Porras JA, et al. Plasma visfatin levels and gene expression in morbidly obese women with associated fatty liver disease. Clin Biochem 2013;46:202-8
   PubMed Web of Science ®Google Scholar
• Neish AS. Microbes in gastrointestinal health and disease. Gastroenterology 2009;136:65-80
   PubMed Web of Science ®Google Scholar
• Velagapudi VR, Hezaveh R, Reigstad CS, et al. The gut microbiota modulate host energy and lipid metabolism in mice. J Lipid Res 2010;51:1101-12
   PubMed Web of Science ®Google Scholar
• Backhed F, Ding H, Wang T, et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci USA 2004;101:15718-23
   PubMed Web of Science ®Google Scholar
• Turnbaugh PJ, Ley RE, Mahowald MA, et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006;444:1027-31
   PubMed Web of Science ®Google Scholar
• Ridaura VK, Faith JJ, Rey FE, et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science 2013;341:12412-14
   Web of Science ®Google Scholar
• Vance DE. Role of phosphatidylcholine biosynthesis in the regulation of lipoprotein homeostasis. Curr Opin Lipidol 2008;19:229-34
   PubMed Web of Science ®Google Scholar
• Spencer MD, Hamp TJ, Reid RW, et al. Association between composition of the human gastrointestinal microbiome and development of fatty liver with choline deficiency. Gastroenterology 2011;140:976-86
   PubMed Web of Science ®Google Scholar
• Dumas ME, Barton RH, Toye A, et al. Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice. Proc Natl Acad Sci USA 2006;103:12511-16
   PubMed Web of Science ®Google Scholar
• Wang Z, Klipfell E, Bennett BJ, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 2011;472:57-63
   PubMed Web of Science ®Google Scholar
• Martin FP, Wang Y, Sprenger N, et al. Probiotic modulation of symbiotic gut microbial–host metabolic interactions in a humanized microbiome mouse model. Mol Syst Biol 2008;4:1-15
   Web of Science ®Google Scholar
• Eric M, Brown Sadarangani M, Finlay BB. The role of the immune system in governing host-microbe interactions in the intestine. Nat Immunol 2013;14:660-7
   PubMed Web of Science ®Google Scholar
• Abreu MT. Toll-like receptor signaling in the intestinal epithelium: how bacterial recognition shapes intestinal function. Nat Rev Immunol 2010;10:131-44
   PubMed Web of Science ®Google Scholar
• Cani PD, Amar J, Iglesias MA, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007;56:1761-72
   PubMed Web of Science ®Google Scholar
• Cani PD, Bibiloni R, Knauf C, et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 2008;57:1470-81
   PubMed Web of Science ®Google Scholar
• Furet JP, Kong LC, Tap J, et al. Differential adaptation of human gut microbiota to bariatric surgery-induced weight loss: links with metabolic and low-grade inflammation markers. Diabetes 2010;59:3049-57
   PubMed Web of Science ®Google Scholar
• Mouzaki M, Comelli EM, Arendt BM, et al. Intestinal microbiota in patients with non-alcoholic fatty liver disease. Hepatology 2013;58:120-7
   PubMed Web of Science ®Google Scholar
• Wigg AJ, Roberts-Thomson IC, Dymock RB, et al. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut 2001;48:206-11
   PubMed Web of Science ®Google Scholar
• Shanab AA, Scully P, Crosbie O, et al. Small intestinal bacterial overgrowth in nonalcoholic steatohepatitis: association with Toll-like receptor 4 expression and plasma levels of interleukin 8. Dig Dis Sci 2011;56:1524-34
   PubMed Web of Science ®Google Scholar
• Miele L, Valenza V, La Torre G, et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 2009;49:1877-87
   PubMed Web of Science ®Google Scholar
• Ilan Y. Leaky gut and the liver: a role for bacterial translocation in nonalcoholic steatohepatitis. World J Gastroenterol 2012;18:2609-18
   PubMed Web of Science ®Google Scholar
• Million M, Lagier JC, Yahav D, Paul M. Gut bacterial microbiota and obesity. Clin Microbiol Infect 2013;19:305-13
   PubMed Web of Science ®Google Scholar
• El Kasmi KC, Anderson AL, Devereaux MW, et al. Toll-like receptor 4-dependent Kupffer cell activation and liver injury in a novel mouse model of parenteral nutrition and intestinal injury. Hepatology 2012;55:1518-28
   PubMed Web of Science ®Google Scholar
• Henao-Mejia J, Elinav E, Jin C, et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 2012;482:179-85
   PubMed Web of Science ®Google Scholar
• Amar J, Chabo C, Waget A, et al. Intestinal mucosal adherence and translocation of commensal bacteria at the early onset of type 2 diabetes: molecular mechanisms and probiotic treatment. EMBO Mol Med 2011;3:559-72
   PubMed Web of Science ®Google Scholar
• Zhu L, Baker SS, Gill C, et al. Characterization of gut microbiomes in non-alcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology 2013;57:601-9
   PubMed Web of Science ®Google Scholar
• Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and stroke statistics–2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009;119:480-6
   PubMed Web of Science ®Google Scholar
• Ekstedt M, Franzén LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006;44:865-73
   PubMed Web of Science ®Google Scholar
• Söderberg C, Stål P, Askling J, et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 2010;51:595-602
   PubMed Web of Science ®Google Scholar
• Adams LA, Lymp JF, St Sauver J, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005;129:113-21
   PubMed Web of Science ®Google Scholar
• Martin G, Nemoto M, Gelman L, et al. The human fatty acid transport protein1 (SLC27A1; FATP-1) cDNA and gene: organization, chromosomal localization, and expression. Genomics 2000;66:296-304
   PubMed Web of Science ®Google Scholar
• Ge F, Zhou S, Hu C, et al. Insulin- and leptin-regulated fatty acid uptake plays a key causal role in hepatic steatosis in mice with intact leptin signaling but not in ob/ob or db/db mice. Am J Physiol Gastrointest Liver Physiol 2010;299:855-66
   PubMed Web of Science ®Google Scholar
• Zhou SL, Stump D, Kiang CL, et al. Mitochondrial aspartate aminotransferase expressed on the surface of 3T3-L1 adipocytes mediates saturable fatty acid uptake. Proc Soc Exp Biol Med 1995;208:263-70
   PubMed Web of Science ®Google Scholar
• Trigatti BL, Anderson RG, Gerber GE. Identification of caveolin-1 as a fatty acid binding protein. Biochem Biophys Res Commun 1999;255:34-9
   PubMed Web of Science ®Google Scholar
• Postic C, Girard J. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J Clin Invest 2008;118:829-38
   PubMed Web of Science ®Google Scholar